Nexalin Technology, Inc. Segments Disclosure
NOTE 10 — SEGMENT INFORMATION
The Company operates as a single reportable segment, consisting of the design and development of innovative neurostimulation products. The Company’s focus is on treating mental health conditions without reliance on drugs or psychotherapy.
Consistent with its operational structure, the Chief Executive Officer, who serves as the chief operating decision maker (CODM), manages and allocates resources on a consolidated basis. Financial performance is evaluated based on consolidated net loss, which is also the primary measure used to allocate resources, assess operational performance, set targets, forecast results, and guide strategic decisions, including investments in research and development and commercialization activities.
The CODM monitors segment performance using consolidated net loss and total consolidated assets, which are reported on the consolidated statements of operations and balance sheets, respectively. Consolidated net loss is compared against budgeted amounts on a quarterly basis to evaluate performance.
The following table summarizes financial information for the Company’s single reportable segment and reconciles to consolidated net loss:
| For the Year Ended December 31, |
||||||||
| 2025 | 2024 | |||||||
| Revenue:(b) | ||||||||
| US | $ | 111,346 | $ | 83,473 | ||||
| International | 190,301 | 85,248 | ||||||
| Total Revenue | 301,647 | 168,721 | ||||||
| Less: | ||||||||
| Cost of revenues (excluding amortization and depreciation) | 61,373 | 36,593 | ||||||
| Research and development expense (excluding share-based compensation expense): | ||||||||
| Clinical trials | 138,933 | 87,492 | ||||||
| EDC build | 170,500 | |||||||
| Halo project | 644,014 | 534,527 | ||||||
| SYNC project | 58,813 | 102,565 | ||||||
| Other research and development(a) | 71,262 | 66,300 | ||||||
| General and administrative and Salaries and benefits expense (excluding stock based compensation and amortization expense) | 3,132,723 | 2,553,459 | ||||||
| Amortization | 21,538 | 15,107 | ||||||
| Stock based compensation | 3,123,263 | 3,560,509 | ||||||
| Professional fees | 1,270,109 | 966,815 | ||||||
| Interest income, net | (8,240 | ) | (3,193 | ) | ||||
| Equity in net income from equity method investees | 1,048 | (4,851 | ) | |||||
| Other income | (161,508 | ) | (139,420 | ) | ||||
| Segment net loss | (8,222,181 | ) | (7,607,182 | ) | ||||
| Reconciliation of net loss | ||||||||
| Adjustments and reconciling items | ||||||||
| Consolidated net loss | $ | (8,222,181 | ) | $ | (7,607,182 | ) | ||
| (a) | Other research and development expenses primarily consist of facilities charges, third party consultant costs, costs related to other product candidates, and other unallocated costs. |
| (b) | Revenue concentrations are reflected in Note 8. |
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Mar 25, 2026 | Showing above |
| 2024 | Mar 14, 2025 | |
About Segments Disclosures
Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.
Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.